Camil Sayegh，Phd
UCB RA Pharma的补充生物学和宏细胞肽平台的负责人
简介
我在蒙特利尔默克斯博斯科斯研究中心开始了我的职业生涯（Merck＆Co，Canada）。这是我学到的很棒的体验，然后磨练了我作为项目领导者的药物狩猎能力。我发起的项目导致了PH2临床候选人。此外，我有机会评估许可机会作为科学专家。在关闭Merck FroSST研究网站之后，我共同创立了一家生物技术公司，在抗病毒研究领域拥有2个领先的PIS。通过这项努力，我们试图利用奎商省的默克定向捐款，以资助我们的努力。此后不久，我加入了蒙特利尔的新生顶点药学研究现场作为生物学副主任。此外，我最近在McGill的Desautels of Management的迷你MBA计划上完成了一项迷你MBA计划，我收购了我在职业中纳入的几个核心竞争力。我对Vertex的经验非常富有成效和令人满意。我为在IBD的研究策略中提供了贡献，并提供有机会向董事会提供。 I’ve led a change in research directions that saw us build a research strategy in kidney diseases with strong underlying causal genetics. To support our efforts, I built our research capabilities including hiring key people, acquiring technologies, and developing strategic collaboration networks. We created a vibrant culture for our site that was focused on a clear vision of excellence aimed at delivering transformative medicines in diseases with high unmet need. I joined RA Pharmaceuticals in June 2017, an exciting and promising start-up focused on targeting the complement pathway. In my new role, I am building on my expertise in kidney diseases and immunological disorders, developing competencies in advancing biologicals, and honing my leadership skills in a start-up setting.
议程会议
主题演讲由会话椅和主题演讲与活Q＆A - 发现和开发Zilucoplan，一种补体C5的大环肽抑制剂
上午10:15查看会话